Cellectis/$CLLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cellectis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Ticker
$CLLS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
219
ISIN
US15117K1034
Website
Cellectis Metrics
BasicAdvanced
$106M
-
-$0.62
3.28
-
Price and volume
Market cap
$106M
Beta
3.28
52-week high
$2.43
52-week low
$1.10
Average daily volume
51K
Financial strength
Current ratio
1.672
Quick ratio
0.942
Long term debt to equity
72.437
Total debt to equity
82.808
Interest coverage (TTM)
-7.09%
Profitability
EBITDA (TTM)
-41.047
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-110.57%
Operating margin (TTM)
-96.52%
Effective tax rate (TTM)
-0.43%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-9.19%
Return on equity (TTM)
-58.55%
Valuation
Price to revenue (TTM)
2.586
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
5.628
Free cash flow yield (TTM)
17.77%
Free cash flow per share (TTM)
25.77%
Growth
Revenue change (TTM)
351.26%
Earnings per share change (TTM)
-55.51%
3-year revenue growth (CAGR)
55.96%
10-year revenue growth (CAGR)
5.19%
3-year earnings per share growth (CAGR)
-40.56%
10-year earnings per share growth (CAGR)
5.20%
What the Analysts think about Cellectis
Analyst ratings (Buy, Hold, Sell) for Cellectis stock.
Cellectis Financial Performance
Revenues and expenses
Cellectis Earnings Performance
Company profitability
Cellectis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cellectis stock?
Cellectis (CLLS) has a market cap of $106M as of June 30, 2025.
What is the P/E ratio for Cellectis stock?
The price to earnings (P/E) ratio for Cellectis (CLLS) stock is 0 as of June 30, 2025.
Does Cellectis stock pay dividends?
No, Cellectis (CLLS) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Cellectis dividend payment date?
Cellectis (CLLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectis?
Cellectis (CLLS) has a beta rating of 3.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.